Drug Trial Radar · NCT07200375
An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Sep 29, 2025
Primary completion
Sep 29, 2029
Study completion Sep 29, 2029
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Oct 1, 2025
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will investigate how well glofitamab-based therapy works and how safe it is in Chinese adult participants with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
Conditions
- Diffuse Large B-Cell Lymphoma
Interventions
GlofitamabDrug
Participants will receive glofitamab as part of a cancer-treatment regimen in a real-world setting. No intervention will be administered by study investigators.
Primary outcomes
What the sponsor says the trial is designed to measure.
- real-world Progression-Free Survival (rwPFS)Time frame: Up to approximately 4 years
Locations
22 sites in 2 countries. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, China · Recruiting
Peking University Third Hospital
Beijing, China · Recruiting
The First Bethune Hospital of Jilin University
Changchun, China · Recruiting
West China Hospital of Sichuan University
Chengdu, China · Recruiting
Guangdong Provincial People's Hospital
Guangzhou, China · Recruiting
Harbin Medical University Cancer Hospital
Harbin, China · Recruiting
Shandong Cancer Hospital
Jinan, China · Recruiting
The Second Affiliated Hospital of Nanchang University
Nanchang, China · Recruiting
The First Affiliated Hospital of Ningbo University
Ningbo, China · Recruiting
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, China · Recruiting
Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, China · Recruiting
Tianjin Cancer Hospital
Tianjin, China · Recruiting
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, China · Recruiting
Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology
Wuhan, China · Recruiting
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
Wuhan, China · Recruiting
The First Affiliated Hospital of Xian Jiao Tong University
Xi'an, China · Recruiting
Yantai Yu Huangding Hospital
Yantai, China · Recruiting
Henan Cancer Hospital
Zhengzhou, China · Recruiting
Cancer Hospital Chinese Academy of Medical Sciences.
Langfang, Hebei, China · Recruiting
Chinese Academy of Medical Sciences Hematology Hospital;Lymphoma Diagnosis and Treatment Center
Tianjin, Tianjin Municipality, China · Recruiting
Prince of Wales Hospital
Hong Kong, Hong Kong · Recruiting
Queen Mary Hospital
Hong Kong, Hong Kong · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.